NorthStar, Convergent ink Ac-225 supply deal

By staff writers

March 9, 2022 -- NorthStar Medical Radioisotopes and Convergent Therapeutics have entered into a supply agreement for the actinium-225 (Ac-225) medical radioisotope.

Under the deal, NorthStar's Ac-225, a radioactive alpha-particle emitter, will be used in Convergent's proprietary drug candidate, CONV 01-α. The drug is a monoclonal antibody conjugated with actinium-225.

The drug candidate is a major component of Convergent's peptide receptor radionuclide therapy (PRRT) technology. PRRT targets prostate-specific membrane antigen present in prostate cancer cells.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking